

Preparation of synthetically challenging nucleotides using cyanoethyl P-imidazolides and microwaves

Malwina Strenkowska, Przemysław Wanat, Marcin Ziemniak, Jacek Jemielity,* and
Joanna Kowalska*

*Division of Biophysics, Institute of Experimental Physics, Faculty of Physics, University
of Warsaw, Zwirki i Wigury 93, 02-089 Warsaw, Poland*


Supporting Information

List of content

I.	Supplementary figures	3
II.	Supplementary table.	6
III.	Experimental procedures	7
1.	General information.	7
2.	Preparation and characterization of phosphorylating reagents 1a and 1b.	7
3.	Preparation of starting materials.	7
3.1.	Synthesis of nucleoside phosphorimidazolides (AMP-Im, GMP-Im).	8
3.2.	Thiophosphorylation of nucleosides.	8
3.3.	Preparation of nucleoside 5'-O-boranophosphates.....	8
3.4.	Preparation of nucleoside 5'-O-(2-thiodiphosphates) and 5'-O-(2-selenodiphosphates)	9
3.5.	Preparation of nucleoside 5'-O-imidodiphosphates	9
3.6.	Preparation of nucleoside 5'-O-methylenebisphosphonates	9
4.	General procedures for the phosphorylation reactions by means of 1a and 1b (synthesis of 2-24)	10
4.1.	Conventional synthesis (2-14, 16-23).....	10
4.2.	Microwave-assisted synthesis (compounds 5, 7, 10, 13, 15, 18, 24).	10
5.	Synthesis and characterization data for the compounds 2-24.	10

5.1.	Guanosine 5'-O-(1-thiodiphosphate); GDP α S (2)	10
5.2.	Guanosine 5'-O-(1-boranodiphosphate); GDP α BH ₃ (3).....	10
5.3.	Adenosine 5'-O-(1-thiodiphosphate); ADP α S (4).	11
5.3.1.	Microwave assisted synthesis of (4).	11
5.4.	Adenosine 5'-O-(1-boranodiphosphate); ADP α BH ₃ (5).....	11
5.4.1.	Microwave assisted synthesis of (5).	11
5.5.	Uridine 5'-O-(1-thiodiphosphate); UDP α S (6).	11
5.6.	N ⁷ -methylguanosine 5'-O-(1-thiodiphosphate) m ⁷ GDP α S (7).	11
5.6.1.	Microwave assisted synthesis of (7).	12
5.7.	Uridine 2',3'-O,O-cyclothiophosphate 5'-O-(1-thiodiphosphate); 2',3'-cyc-P _S -UDP α S (8).....	12
5.8.	Adenosine 5'-O-(1,2-dithiodiphosphate) ADP α S β S (9)	12
5.9.	Guanosine 5'-O-(1,2-dithiodiphosphate) GDP α S β S (10).....	12
5.9.1.	Microwave assisted synthesis of (10).	12
5.10.	Adenosine 5'-O-(2-thiotriphosphate); ATP β S (11).	12
5.11.	Guanosine 5'-O-(2-thiotriphosphate); GTP β S (12).	13
5.12.	Adenosine 5'-O-(2-boranotriphosphate); ATP β BH ₃ (13).....	13
5.12.1.	Microwave assisted synthesis of (13).	13
5.13.	Guanosine 5'-O-(2-boranotriphosphate); GTP β BH ₃ (14).....	13
5.14.	Adenosine 5'-O-(2-selenotriphosphate) ATP β Se (15) (microwave assisted synthesis)	13
5.15.	Guanosine 5'-O-(2-selenotriphosphate) GTP β Se (16).	13
5.16.	Adenosine 5'-O-(1,2-methylenetriphosphate); ppCH ₂ pA (17).	14
5.17.	Guanosine 5'-O-(1,2-methylenetriphosphate), ppCH ₂ pG (18).....	14
5.17.1.	Microwave assisted synthesis of (18).	14
5.18.	Adenosine 5'-O-(1,2-imidotriphosphate) ppNHpA (19).	14
5.19.	Guanosine 5'-O-(1,2-imidotriphosphate) ppNHpG (20).....	14
5.20.	Adenosine 5'-O-tetraphosphate ppppA (21).	14
5.21.	N ⁷ -methylguanosine 5'-O-(2,3-methylenetetraphosphate); ppCH ₂ pp(m ⁷ G) (22).	14
5.22.	N ⁷ -methylguanosine 5'-O-(1,2-methylenetetraphosphate); pppCH ₂ p(m ⁷ G) (23).	15
5.23.	Guanosine 5'-O-(1,2-methylene-3-thiotriphosphate); p ₅ pCH ₂ pG (24) (microwave assisted synthesis).....	15
6.	Supplementary references.	15
IV.	HPLC profiles, HRMS and NMR spectra	16

I. Supplementary figures



Scheme S1. (A) Synthesis of **1a** and **1b**. (B) Application of **1a** and **1b** to nucleoside oligophosphate synthesis. (C) CE removal reaction in the presence of DTT




Fig. S1. Comparison of exemplary modified pyrophosphate bond formation reactions carried out under conventional conditions (RT) and in the presence of microwave irradiation. Reaction conditions are given in paragraph 5.9.




Fig. S2. Synthesis of starting materials reported for the first time. **A)** Synthesis of nucleoside boranophosphates (paragraph 3.3) – starting materials for the preparation of nucleoside 1-boranodiphosphates (**3** and **5**) and **B)** nucleoside 2-selenodiphosphates (paragraph 3.4) – starting materials for the preparation of nucleoside 2-selenotriphosphates (**15** and **16**).

Fig. S3. One-pot synthesis of nucleoside 2-boranotriphosphates from corresponding 5'-phosphorimidazolides











Fig. S4. Exemplary RP HPLC profiles from microwave-assisted oligophosphate chain elongation reactions by means of reagents 1a and 1b at different time points.

- Synthesis of ADPaBH₃-CE from adenosine 5'-boranophosphate (AMPBH₃) and **1a**
- Synthesis of m⁷GDPαS-CE from 7-methylguanosine 5'-thiophosphate and **1a**
- Synthesis of CE-p₃pCH₂pG from guanosine 5'-methylenebisphosphonate and **1b**
- Synthesis of CE-ppCH₂pG from guanosine 5'-methylenediphosphate and **1a**
- Synthesis of ATPβBH₃-CE from adenosine 5'-(2-selenodiphosphate) and **1a**
- Synthesis of GDPαSβS-CE from guanosine 5'- thiophosphate and **1b**
- Synthesis of ATPβSe-CE from adenosine 5'-(2-selenodiphosphate) and **1a**

II. Supplementary table.

Table S1. Microwave-assisted synthesis of selected nucleotides performed without Sephadex isolation of the final product.

Reaction product	Starting materials	Coupling time ^[a] / HPLC conversion into CE-nucleotide	HPLC profile after coupling reaction	CE removal time ^[b]
GDP	GMP + 1a	15 min/100%		15 min
GDP α S (2)	GMPS + 1a	30 min/91%		20 min
UDP α S (6)	UMPS + 1a	30 min/86%		30 min
ADP α S β S (9)	AMPS + 1b	30 min/88%		30 min
ppCH ₂ pA (17)	pCH ₂ pA + 1a	30 min/82%		30 min
ppNHpA (19)	pNHpA + 1a	30 min/95%		15 min
p ₄ A (21)	ATP + 1a	30 min/86%		15 min

[a] reaction conditions: 8 equiv MgCl₂, DMF

[b] reaction conditions: 10–15% DBU; DMF, DTT; μ w: 40 °C, closed vessel, dynamic power max. 10 W.; reaction progress was followed by RP HPLC equipped with UV-VIS detector and coupled with electrospray ionization (ESI) quadrupole mass spectrometer.

III. Experimental procedures

1. General information.

Synthesized nucleotides were purified by ion-exchange chromatography on DEAE-Sephadex A-25 (HCO_3^- form) column. A column was loaded with reaction mixture and washed through with excess of water to remove metal (II) salt/EDTA complex. Then, the nucleotides were eluted using a linear gradient of triethylammonium bicarbonate (TEAB) in deionized water. After evaporation under reduced pressure with repeated additions of ethanol to decompose TEAB, compounds were isolated as triethylammonium (TEA) salts. Yields were calculated on the basis of either sample weight or (preferably) optical milliunits (opt.mu) of the product. Optical unit measurements were performed in 0.1 M phosphate buffer (pH = 7 or pH = 6 for $m^7\text{G}$ nucleotides) at 260 nm.

Analytical HPLC was performed on Agilent Tech. Series 1200 using Supelcosil LC-18-T HPLC column (4.6 x 250 mm, flow rate 1.3 mL/min) with a linear gradient 0–25% of methanol in 0.05 M ammonium acetate buffer (pH 5.9) in 15 min, UV-detection at 260 nm and fluorescence detection (excitation at 280 nm and detection at 337 nm). Semi-preparative HPLC was performed on the same apparatus equipped with Discovery RP Amide C-16 HPLC column (25cm x 21.2 mm, 5 μm , flow rate 5.0 mL/min) with linear gradients of acetonitrile in 0.05 M ammonium acetate buffer (pH 5.9) and UV-detection at 260 nm. The structure and homogeneity of each final product was confirmed by RP HPLC, high resolution mass spectrometry HRMS (ESI⁺) and ^1H NMR and ^{31}P NMR spectroscopy. Intermediate products were characterized by low resolution MS (ESI⁺) or NMR. Mass spectra were recorded on Thermo Scientific LTQ Orbitrap Velos (high resolution) and AB Sciex API 3200 (low resolution) spectrometers. ^1H NMR and ^{31}P NMR spectra were recorded at 25°C on a Varian UNITY-plus spectrometer at 399.94 MHz and 161.90 MHz, respectively. ^1H NMR chemical shifts were reported to sodium 3-trimethylsilyl-[2,2,3,3-D₄]-propionate (TSP) in D₂O as an internal standard. ^{31}P NMR chemical shifts were reported to 20% phosphorus acid in D₂O as an external standard.

The reactions involving microwave irradiation were conducted in heavy-walled glass 10-mL pressurized vials and CEM's proprietary "snap-on" caps. The microwave heating was performed in a CEM Discover single-mode microwave cavity, using dynamic power mode with maximum power of 10 W and at 45 ± 1 °C and at 2450 MHz. The reaction mixtures were stirred with a magnetic stir bar during the irradiation. The temperature, pressure and power were monitored during the course of reactions using the provided software (standard infrared temperature sensor).

Solvents and chemical reagents were purchased from Sigma-Aldrich and used without any pre-treatment unless otherwise stated.

2. Preparation and characterization of phosphorylating reagents **1a** and **1b**.

(2-Cyanoethyl) phosphate TEA salt was obtained from commercially available (2-cyanoethyl) phosphate barium salt dihydrate (Sigma-Aldrich). A suspension of 5 g (15.5 mmol) of the barium salt in 100 mL of water was passed through Dowex 50 W x 8 (200–400 mesh) resin in H^+ form and eluted with water (~500 mL). The eluate was collected into a round bottom-flask containing a solution of TEA (3.2 mL) in ethanol (100 mL), evaporated and dried in vacuum over P_4O_{10} . (2-Cyanoethyl) thiophosphate sodium salt was prepared from trisodium thiophosphate dodecahydrate according to procedures described by Burgers *et al.*¹ and converted into TEA following analogous procedure as for (2-cyanoethyl) phosphate. Thereafter, an appropriate starting material, (2-cyanoethyl) phosphate or (2-cyanoethyl) thiophosphate TEA salt, was mixed with imidazole (10 equiv., 10.54 g, 0.155 mol), 2,2'-dithiodipyridine (3 equiv., 10.13 g, 46 mmol), DMF (25 mL), triethylamine (3 equiv., 4 mL, 30 mmol) and triphenylphosphine (3 equiv., 12.0 g, 46 mmol), and the mixture was stirred for 6–8 h. The product was precipitated from the reaction mixture with a solution of anhydrous LiClO_4 (4 equiv., 6.58 g, 61.9 mmol) in dry acetonitrile (250 mL). After cooling at 4°C, the precipitate was filtered off, washed repeatedly with cold, dry acetonitrile, and dried in vacuum over P_4O_{10} . Reagents **1a** and **1b** can be stored at 4 °C in a closed vessel for several months. Yields: **1a** – 2.86 g (13.8 mmol, 89%) from 5g (15.5 mmol) of (2-cyanoethyl) phosphate barium salt dihydrate; **1b** – 2.51 g (11.25 mmol, 89%) from 5g (12.6 mmol) of commercial trisodium thiophosphate dodecahydrate.

1a: ^1H NMR (400 MHz, D₂O, 25 °C) δ = 7.99 (s, 1 H), 7.37 (s, 1 H), 7.18 (s, 1 H), 4.07 (td, J = 5.8, 6.6 Hz, 2 H), 2.81 (t, J = 5.8 Hz, 32 H); ^{31}P NMR (162 MHz, D₂O, 25 °C) δ = -7.65 (t, J = 6.6 Hz, 1 P); MS (ESI⁺) Calcd m/z for $\text{C}_6\text{H}_7\text{N}_3\text{O}_2\text{P}^+$ (M-H⁺) 200.0, found 200.0.

1b: ^1H NMR (400 MHz, D₂O, 25 °C) δ = 8.00 (s, 1 H), 7.38 (s, 1 H), 7.14 (br. s., 1 H), 2.93 (td, J = 6.8, 16.9 Hz, 2 H), 2.65 (t, J = 6.8 Hz, 2 H); ^{31}P NMR (162 MHz, D₂O, 25 °C) δ = 11.29 (t, J = 16.9 Hz, 1 P); MS (ESI⁺) Calcd m/z for $\text{C}_6\text{H}_7\text{N}_3\text{O}_2\text{PS}^+$ (M-H⁺) 216.0, found 216.0.

3. Preparation of starting materials.

Thiophosphate, selenophosphate and boranophosphate TEA salts were obtained as described earlier (Kowalska et al. 2007, Kowalska et al. 2009, Nahum and Fischer 2004). ATP TEA salt was obtained from commercial ATP sodium salt by passing through Dowex 50 W x 8 (200–400 mesh) in TEA form. $m^7\text{GppCH}_2\text{p}$ TEA salt was obtained as described earlier (Rydzik et al. 2009). 7-methylguanosine was prepared

from guanosine by methylation with CH_3I similar to previously reported procedure.⁵ Nucleoside phosphorimidazolides, AMP-Im, GMP-Im, were prepared according to Mukaiyama and Hashimoto as described in general procedure 3.1. Guanosine and adenosine 5'-*O*-(H-phosphonates) were prepared as described by Yoshikawa et al. (1970). Modified nucleoside 5'-*O*-monophosphates and 5'-*O*-diphosphates were prepared as described below (general procedures 3.1–3.5).

3.1. Synthesis of nucleoside phosphorimidazolides (AMP-Im, GMP-Im).

The appropriate starting material (nucleotide TEA salt) (0.010 mol, 1 equiv.), imidazole (6.8 g, 0.10 mol, 10 equiv.), and 2,2'-dithiodipyridine (6.6 g, 0.030 mol, 3 equiv.) were mixed in 30 mL DMF. Triethylamine (4.3 mL, 3.0 g, 0.030 mol, 3 equiv.) and triphenylphosphine (7.9 g, 0.030 mol, 3 equiv.) were added, and the mixture was stirred for 6–8 h. The product was precipitated from reaction mixture with anhydrous NaClO_4 (0.040 mol, 4.9 g) solution in dry acetone (300 mL). After cooling at 4°C, the precipitate was filtered, washed repeatedly with cold, dry acetone, and dried in vacuum over P_4O_{10} .

3.2. Thiophosphorylation of nucleosides.

An appropriate nucleoside (1 mmol) dried overnight in vacuum over P_4O_{10} was suspended in trimethyl phosphate (10 mL) and placed on ice-bath. After cooling to 0 °C, 2,6-lutidine (4 mmol, 465 μL) and freshly distilled PSCl_3 (3 mmol, 305 μL) was added into the mixture and reaction was stirred at 0 °C until the disappearance of the starting material as determined by HPLC profile (1–6 h). Then reaction could be stopped by addition of 0.7 M TEAB (pH = 7) to obtain 5'-*O*-monothiophosphates or continued until 5'-*O*-monothiophosphate was converted into nucleoside 2',3'-*O*-cyclothiophosphate-5'-*O*-(thiophosphate) and then stopped the same way. The solution was washed 3 times with ethyl acetate and then products were purified by DEAE-Sephadex and isolated as TEA salts. Products containing some inorganic contamination after chromatography, were additionally precipitated with acetonitrile, centrifuged and freeze-dried.

Guanosine 5'-*O*-monothiophosphate, GMPS. GMPS (428 mg, 9032 opt.mu, 0.750 mmol, 76%; TEA salt) was obtained starting from guanosine (315 mg, 0.980 mmol) following the general procedure of thiophosphorylation of nucleosides. Reaction time: 3 h. R_t = 3.0 min; ^{31}P NMR (162 MHz, D_2O , 25 °C) δ = 44.09 (s, 1P); MS (ESI⁺) Calcd m/z for $\text{C}_{10}\text{H}_{13}\text{N}_5\text{O}_7\text{P}^-$ (M-H⁺) 378.0, found 378.0; Exemplary previous synthesis: Eckstein F., *JACS*. **1970**, 92, 4718–4723.

7-methylguanosine 5'-*O*-monothiophosphate, m⁷GMPS. m⁷GMPS (190 mg, 4000 opt.mu, 0.350 mmol, 70%; TEA salt) was obtained starting from guanosine (170 mg, 0.51 mmol) following the general procedure of thiophosphorylation of

nucleosides. Reaction time: 3 h. R_t = 5.5 min; ^{31}P NMR (162 MHz, D_2O , 25 °C) δ = 46.80 (s, 1P); MS (ESI⁺) Calcd m/z for $\text{C}_{11}\text{H}_{15}\text{N}_5\text{O}_7\text{P}^-$ (M-H⁺) 392.0, found 392.0. Exemplary previous synthesis: Kowalska J. et al. *RNA* **2008**, 14, 1–13.

Adenosine 5'-*O*-monothiophosphate, AMPS. AMPS (371 mg, 10280 opt.mu, 0.685 mmol, 61%; TEA salt) was obtained starting from adenosine (300 mg, 1.123 mmol) following the general procedure of thiophosphorylation of nucleosides. Reaction time: 5 h. R_t = 4.6 min; ^{31}P NMR (162 MHz, D_2O , 25 °C) δ = 47.45 (s, 1P); MS (ESI⁺) Calcd m/z for $\text{C}_{10}\text{H}_{13}\text{N}_5\text{O}_6\text{P}^-$ (M-H⁺) 362.0, found 362.0. Exemplary previous synthesis: Eckstein F., *JACS*. **1970**, 92, 4718–4723.

Uridine 5'-*O*-monothiophosphate, UMPS. UMPS (650 mg, 11780 opt.mu 1.220 mmol, 75%; TEA salt) was obtained starting from uridine (500 mg, 1.640 mmol) following the general procedure of thiophosphorylation of nucleosides. Reaction time: 2 h. R_t = 2.4 min; ^{31}P NMR (162 MHz, D_2O , 25 °C) δ = 45.75 (s, 1P); MS (ESI⁺) Calcd m/z for $\text{C}_9\text{H}_{12}\text{N}_2\text{O}_8\text{P}^-$ (M-H⁺) 339.0, found 339.0. Exemplary previous synthesis: Eckstein F., *JACS*. **1970**, 92, 4718–4723.

Uridine 2',3'-*O*-cyclothiophosphate 5'-*O*-thiophosphate, 2',3'-cyc- P_S -UMPS. 2',3'-cyc- P_S -UMPS. (360 mg, 4850 opt.mu, 0.502 mmol, 51%; TEA salt) was obtained starting from uridine (300 mg, 0.984 mmol) following the general procedure of thiophosphorylation of nucleosides. Reaction time: 8 h. R_t = 2.3 min; ^{31}P NMR (162 MHz, D_2O , 25 °C) δ = 76.10 (t, J = 6.3 Hz, 1P), 49.44 (s, 1P); MS (ESI⁺) Calcd m/z for $\text{C}_9\text{H}_{11}\text{N}_2\text{O}_9\text{P}_2\text{S}_2^-$ (M-H⁺) 417.0, found 417.0; Exemplary previous synthesis: Eckstein F., *JACS*. **1970**, 92, 4718–4723.

3.3. Preparation of nucleoside 5'-*O*-boranophosphates.

Nucleoside-5'-*O*-(H-phosphonate) was placed in a rubber septum capped round-bottom flask under argon atmosphere and suspended in acetonitrile (30 mL/100 mg) Then, N_2O -bis(trimethylsilyl) acetamide (BSA, 15–20 equiv.) was added through a syringe and after 30 min of stirring, BH_3SMe_2 (2 equiv.) was added and the mixture was left for 30 min. An adequate product was released after addition of TEA/MeOH solution. The solution was evaporated to dryness and 3 times re-evaporated from methanol. Obtained crude products were used for the reaction with **1a** without further purification. For the purpose of NMR characterization, the products were purified on DEAE-Sephadex and isolated as TEA salts and the preparative yields are given for these syntheses.

Adenosine 5'-*O*-monoboranophosphate, AMPBH₃; AMPBH₃ (305 mg, 9720 opt.mu, 0.65 mmol, 54%; TEA salt) was obtained starting from adenosine H-phosphonate triethylammonium salt (540 mg, 18,000 opt.mu, 1.2 mmol) following the general procedure. R_t = 7.5 min; ^1H NMR (400 MHz, D_2O , 25 °C) δ = 8.54 (s, 1 H), 8.23 (s, 1 H), 6.14 (d, J = 5.7 Hz, 1 H), 4.76 (dd, J = 5.2, 5.7 Hz, 1 H), 4.50 (dd, J = 3.2, 5.2 Hz, 1 H), 4.39 (q, J = 3.2 Hz, 1 H), 4.16–

4.05 (m, 2 H), 3.20 (q, $J = 7.5$ Hz, 6 H), 1.28 (t, $J = 7.5$ Hz, 9 H), 0.36 (q, $J = 88.0$ Hz, 3 H); ^{31}P NMR (162 MHz, D_2O , 25 °C) $\delta = 88.14$ (q, $J = 143$ Hz, 1P) MS (ESI $^-$) Calcd m/z for $\text{C}_{10}\text{H}_{16}\text{BN}_5\text{O}_6\text{P}^-$ (M-H $^+$) 344.1, found 344.1.

Guanosine 5'-O-monoboranophosphate, GMPBH $_3$; GMPBH $_3$ (650 mg, 16560 opt.mu, 1.4 mmol, 60%; TEA salt) was obtained starting from guanosine H-phosphonate (1030 mg, 27600 opt.mu, 2.3 mmol) following the general procedure. $R_t = 5.5$ min; ^1H NMR (400 MHz, D_2O , 25 °C) $\delta = 8.19$ (s, 1 H), 5.93 (d, $J = 6.0$ Hz, 1 H), 4.76 (dd, $J = 4.8$, 6.0 Hz, 1 H), 4.47 (dd, $J = 3.1$, 4.8 Hz, 1 H), 4.32 (q, $J = 3.1$ Hz, 1 H), 4.07–4.00 (m, 1 H), 3.20 (q, $J = 7.5$ Hz, 6 H), 1.28 (t, $J = 7.5$ Hz, 9 H), 0.76–0.14 (m, 3 H) ^{31}P NMR (162 MHz, D_2O , 25 °C) $\delta = 85.80$ (q, $J = 146$ Hz, 1P); MS (ESI $^-$) Calcd m/z for $\text{C}_{10}\text{H}_{16}\text{BN}_5\text{O}_7\text{P}^-$ (M-H $^+$) 360.1, found 360.1.

3.4. Preparation of nucleoside 5'-O-(2-thiodiphosphates) and 5'-O-(2-selenodiphosphates)

Generally, these compounds were synthesized following several previously published procedures (Kowalska et al. 2007; Kowalska et al. 2009). An appropriate nucleoside 5'-O-monophosphate phosphorimidazolide (1 mmol, 1 equiv.), either thiophosphate or selenophosphate TEA salt (2 mmol, 2 equiv.) and anhydrous ZnCl_2 (8 mmol, 8 equiv.) were dissolved in DMF and stirred at RT. After 30 min, the reaction was quenched by addition of solution of EDTA (8 mmol, 8 equiv.) and NaHCO_3 (18 equiv.) in water. Products were purified on DEAE-Sephadex and isolated as TEA salts.

Adenosine 5'-O-(2-thiodiphosphate), ADP βS ; ADP βS (160 mg, 5460 opt.mu, 0.364 mmol, 70%; TEA salt) was obtained starting from AMP-Im (200 mg, 7790 opt.mu, 0.520 mmol, sodium salt) following the general procedure. $R_t = 4.8$ min; ^{31}P NMR (162 MHz, D_2O , 25 °C) $\delta = 30.40$ (d, $J = 29.8$ Hz, 1 P), -11.58 (d, $J = 29.8$ Hz, 1P); MS (ESI $^-$) Calcd m/z for $\text{C}_{10}\text{H}_{14}\text{N}_5\text{O}_9\text{P}_2\text{S}^-$ (M-H $^+$) 442.0, found 442.0. Exemplary previous synthesis: Eckstein F. et al., *Biochemistry*, **1976**, 15, 1685–91.

Guanosine 5'-O-(2-thiodiphosphate), GDP βS ; GDP βS (180 mg, 2820 opt.mu, 0.230 mmol, 79%; TEA salt) was obtained starting from GMP-Im (150 mg, 3570 opt.mu, 0.300 mmol, sodium salt) following the general procedure. $R_t = 3.0$ min; ^{31}P NMR (162 MHz, D_2O , 25 °C) $\delta = 34.69$ (d, $J = 31.4$ Hz, 1 P), -11.57 (d, $J = 31.4$ Hz, 1 P); MS (ESI $^-$) Calcd m/z for $\text{C}_{10}\text{H}_{14}\text{N}_5\text{O}_{10}\text{P}_2\text{S}^-$ (M-H $^+$) 458.0, found 458.0. Exemplary previous synthesis: Eckstein F. et al., *Biochemistry*, **1976**, 15, 1685–91.

Adenosine 5'-O-(2-selenodiphosphate), ADP βSe ; ADP βSe (145 mg, 2900 opt.mu, 0.193 mmol, 25%; TEA salt) was obtained starting from AMP-Im (360 mg, 11680 opt.mu, 0.779 mmol, sodium salt) following the general procedure. After quenching with EDTA/ NaHCO_3 aqueous solution, the mixture was extracted several times with CH_2Cl_2 to to

remove elemental selenium. $R_t = 3.9$ min; ^1H NMR (400 MHz, D_2O , 25 °C) $\delta = 8.57$ (s, 1 H), 8.25 (s, 1 H), 6.11 (d, $J = 5.5$ Hz, 2 H), 4.78 (dd, $J = 5.5$, 4.9 Hz, 1 H), 4.63 (dd, $J = 5.0$, 3.0 Hz, 1 H), 4.35–4.41 (m, 1 H), 4.16–4.31 (m, 2 H), 3.20 (q, $J = 7.6$ Hz, 12 H), 1.28 (t, $J = 7.6$ Hz, 18 H); ^{31}P NMR (162 MHz, D_2O , 25 °C) $\delta = 21.68$ (d, $J = 35.2$ Hz, 1 P) -12.28 (d, $J = 35.2$ Hz, 1 P) MS (ESI $^-$) Calcd m/z for $\text{C}_{10}\text{H}_{14}\text{N}_5\text{O}_9\text{P}_2\text{Se}^-$ (M-H $^+$) 489.9, found 489.9.

Guanosine 5'-O-(2-selenodiphosphate), GDP βSe ; GDP βSe (232 mg, 5720 opt.mu, 0.470 mmol, 65%; TEA salt) was obtained starting from GMP-Im (360 mg, 8820 opt.mu, 0.840 mmol; sodium salt) following the general procedure. After quenching with EDTA/ NaHCO_3 aqueous solution, the mixture was extracted several times with CH_2Cl_2 to remove elemental selenium. $R_t = 2.4$ min; ^1H NMR (400 MHz, D_2O , 25 °C) $\delta = 8.06$ –7.98 (m, 1 H), 5.84 (d, $J = 5.2$ Hz, 1 H), ~4.82–4.78 (overlapped with water, m, 1 H), 4.56–4.51 (m, 1 H), 4.32–4.27 (m, 1 H), 4.23–4.15 (m, 2 H), 3.19 (q, $J = 7.5$ Hz, 12 H), 1.27 (t, $J = 7.5$ Hz, 18 H); ^{31}P NMR (162 MHz, D_2O , 25 °C) $\delta = 26.53$ (d, $J = 37.0$ Hz, 1 P) -12.11 (d, $J = 37.0$ Hz, 1 P); MS (ESI $^-$) Calcd m/z for $\text{C}_{10}\text{H}_{15}\text{N}_5\text{O}_{13}\text{P}_2\text{Se}^-$ (M-H $^+$) 505.9, found 505.9.

3.5. Preparation of nucleoside 5'-O-imidodiphosphates

Generally, these compounds were synthesized following a previously published procedure (Tomasz, J., et al. 1988). Nucleoside (1 mmol) was suspended in 8 mL of trimethyl phosphate and cooled to -8°C. Then, $\text{Cl}_3\text{PNP}(\text{O})\text{Cl}_2$ (3 mmol, 3 equiv.) was added under vigorous stirring. Reaction was maintained at -8°C and was stopped after 2 h by addition of 0.7 M TEAB to pH = 7 and diluted with water. The product was purified on DEAE-Sephadex and isolated as TEA salt.

Adenosine 5'-O-imidodiphosphate, pNHpA; pNHpA (366 mg, 13000 opt.mu, 0.86 mmol, 44%) was obtained starting from 500 mg (28140 opt.mu, 1.82 mmol) of adenosine following the general procedure. $R_t = 5.2$ min; ^{31}P NMR (162 MHz, D_2O , 25 °C) $\delta = 0.95$ (m, 1 P) -0.61 (d, $J = 5.8$ Hz, 1 P); MS (ESI $^-$) Calcd m/z for $\text{C}_{10}\text{H}_{15}\text{N}_6\text{O}_9\text{P}_2^-$ (M-H $^+$) 425.0, found 425.0; Exemplary previous synthesis: Tomasz J. et al., *Nucl. Acids Res.* **1988**, 16, 8645–8664.

Guanosine 5'-O-imidodiphosphate, pNHpG; pNHpG (931 mg, 14280 opt.mu, 134 mmol, 56%) was obtained starting from 600 mg (25400 opt.mu, 2.12 mmol) guanosine following the general procedure. $R_t = 4.1$ min; ^{31}P NMR (162 MHz, D_2O , 25 °C) $\delta = 0.96$ (m, 1P), -0.64 (d, 1P, $J = 5.5$ Hz); MS (ESI $^-$) Calcd m/z for $\text{C}_{10}\text{H}_{15}\text{N}_6\text{O}_{10}\text{P}_2^-$ (M-H $^+$) 441.0, found 441.0; Exemplary previous synthesis: Tomasz J. et al., *Nucl. Acids Res.* **1988**, 16, 8645–8664.

3.6. Preparation of nucleoside 5'-O-methylenebisphosphonates

Generally, these compounds were synthesized following a previously published procedure (Kalek, M. et al. 2005). Solution of methylenebis(phosphonic dichloride) (300 mg, 1.2 mmol, 1.2 equiv.) in 8 mL of trimethyl phosphate cooled to 0 °C was added to a suspension of nucleoside (1 mmol, 1 equiv.) in 8 mL of trimethyl phosphate at 0 °C. The reaction mixture was stirred at 0 °C. After 1 h, 0.7 M aqueous TEAB (to achieve pH 7.0) was added. The product was purified on DEAE-Sephadex and isolated as TEA salt.

Adenosine 5'-O-methylenediphosphate, pCH₂pA; pCH₂pA (376 mg, 10260 opt.mu, 0.86 mmol, 61%; TEA salt) was obtained starting from 300 mg (16880 opt.mu, 1.12 mmol) adenosine following the general procedure. $R_t = 4.4$ min; ^{31}P NMR (162 MHz, D₂O, 25 °C) $\delta = 19.32$ (m, 1P) 15.59 (m, 1P); MS (ESI⁻) Calcd m/z for C₁₁H₁₆N₅O₉P₂⁻ (M-H⁺) 424.0, found 424.0; Exemplary previous synthesis: Kalek M., Jemielity J., Stepinski J., Stolarski R., Darzynkiewicz E., *Tetrahedron Lett.*, **2005**, 46, 2417–2421.

Guanosine 5'-O-methylenediphosphate, pCH₂pG; pCH₂pG (502 mg, 13700 opt.mu, 1.14 mmol, 65%) was obtained starting from 600 mg (25400 opt.mu., 2.12 mmol) guanosine following the general procedure. $R_t = 3.3$ min; ^{31}P NMR (162 MHz, D₂O, 25 °C) $\delta = 19.27$ (m, 1P) 15.70 (dt J = 19.9, 9.8 Hz 1 P); MS (ESI⁻) Calcd m/z for C₁₁H₁₆N₅O₁₀P₂⁻ (M-H⁺) 440.0378, found 440.0; Exemplary previous synthesis: Kalek M., Jemielity J., Stepinski J., Stolarski R., Darzynkiewicz E., *Tetrahedron Lett.*, **2005**, 46, 2417–2421.

4. General procedures for the phosphorylation reactions by means of 1a and 1b (synthesis of 2–24)

4.1. Conventional synthesis (2–14, 16–23).

An appropriate nucleotide (0.30 mmol, 1 equiv., TEA salt) was suspended in 3 mL of DMF. Then, **1a** (186 mg, 0.90 mmol, 3 equiv.) (syntheses **2–8**, **11–24**) or **1b** (201 mg, 0.90 mmol, 3 equiv.) (syntheses **9–10**, **24**) and anhydrous MgCl₂ (228 mg, 2.4 mmol, 8 equiv.) were added to the suspension. In the case of syntheses of **14** and **15** starting materials were generated in situ (due to difficulties in their synthesis and isolation) from nucleoside 5'-phosphorimidazolides NMP-Im (0.300 mmol, 1 equiv.) and triethylammonium boranophosphate (352 mg, 1.8 mmol, 6 equiv.) mixed together with **1a** (186 mg, 0.90 mmol, 3 equiv.) and anhydrous MgCl₂ (228 mg, 2.4 mmol, 8 equiv.) in 3 mL DMF. The mixture was stirred at room temperature until the starting material disappeared, as determined by HPLC. Next, the product was subjected to cyanoethyl group removal (one-pot reaction): The solution was diluted with 3 mL of DMF and 1.1 mL of DBU was added. The reaction was carried out at 50 °C in an open flask protected from moisture (capped with drying tube packed with anhydrous calcium chloride) or alternatively DTT (138 mg, 0.9 mmol, 3 equiv.) was added to the mixture. The reaction was stopped by addition of 1% acetic acid to pH =7, diluted with water and washed 3 times

with ethyl acetate. Finally, products were purified on DEAE-Sephadex and isolated as TEA salts. Exact amounts used for particular reactions, yields and reaction times are provided in section 5.

4.2. Microwave-assisted synthesis (compounds 5, 7, 10, 13, 15, 18, 24).

An appropriate nucleotide (0.1 mmol, TEA salt) was placed in a 10 ml microwave tube and suspended in 1 mL of DMF. Then, **1a** (62 mg, 0.300 mmol, 3 equiv.) (syntheses **5**, **7**, **13**, **18**) or **1b** (67 mg, 0.300 mmol, 3 equiv.) (syntheses **10**, **24**) and anhydrous MgCl₂ (76 mg, 0.8 mmol, 8 equiv.) were added to the suspension. The tube was heated for 10–30 min in the microwave oven using dynamic power mode (parameters: $P_{\text{max}} = 10$ W and $T_{\text{max}} = 45 \pm 1$ °C). Then, 1 mL of DMF, 0.35 mL DBU and DTT (3 equiv.) were added to the mixture to remove the 2-cyanoethyl group. The tube was again heated in the microwave oven using the same parameters as given above. The reaction was stopped by addition of 1% acetic acid to pH =7, diluted with water and washed with ethyl acetate. Products were purified on DEAE-Sephadex and isolated as TEA salts. Exact amounts used for particular reactions, yields and reaction times are provided in section 5.

5. Synthesis and characterization data for the compounds 2–24.

5.1. Guanosine 5'-O-(1-thiodiphosphate); GDPαS (2)

2 (93 mg, 1625 opt.mu, 0.135 mmol, 37%; TEA salt) was obtained starting from 200 mg (4400 opt.mu, 0.365 mmol) of GMPS (TEA salt) following the general procedure **4.1**. Coupling time: 3 d; deprotection time: 5 h. Diastereoisomers D1(**2a**) and D2(**2b**) were later separated on semi-preparative RP HPLC and after repeated freeze-drying, were isolated as ammonium salts.

(**2a**) $R_t = 3.6$ min; ^1H NMR (400 MHz, D₂O, 25 °C) $\delta = 8.24$ (s, 1 H), 5.96 (d, $J = 6.0$ Hz, 1 H), 4.82 (dd, $J = 5.0, 6.0$ Hz, 1 H), 4.57 (dd, $J = 3.2, 5.0$ Hz, 1 H), 4.42–4.37 (m, 1 H), 4.32–4.23 (m, 2 H); ^{31}P NMR (162 MHz, D₂O, 25 °C) $\delta = 82.50$ (m, 1 P) -10.16 (d, $J = 28.8$ Hz, 1 P); HRMS (ESI⁻) Calcd m/z for C₁₀H₁₄N₅O₁₀P₂S⁻ (M-H⁺) 457.9942, found 457.9928; (**2b**) $R_t = 4.1$ min; ^1H NMR (400 MHz, D₂O, 25 °C) $\delta = 8.19$ (s, 1 H), 5.94 (d, $J = 6.0$ Hz, 1 H), 4.82 (dd, $J = 4.5, 6.0$ Hz, 1 H), 4.56 (dd, $J = 2.5, 4.5$ Hz, 1 H), 4.41–4.36 (m, 1 H), 4.29–4.23 (m, 2 H); ^{31}P NMR (162 MHz, D₂O, 25 °C) $\delta = 82.50$ (m, 1 P) -10.16 (d, $J = 28.8$ Hz, 1 P); HRMS (ESI⁻) Calcd m/z for C₁₀H₁₄N₅O₁₀P₂S⁻ (M-H⁺) 457.9942, found 457.9927; Exemplary previous synthesis: Connolly B. et al, *Biochemistry*, **1982**, 21, 1983–1989.

5.2. Guanosine 5'-O-(1-boranodiphosphate); GDPαBH₃ (3)

3 (125 mg, 2280 opt.mu, 0.19 mmol, 62%, TEA salt) was obtained starting from crude GMPBH₃ (3720 opt.mu, 0.31

mmol, TEA salt) following the general procedure 4.1. Coupling time: 24 h; deprotection time: 5 h. Diastereoisomers D1 (**3a**) and D2 (**3b**) were later separated on semi-preparative RP HPLC and after repeated freeze-drying, were isolated as ammonium salts.

(**3a**) $R_t = 4.8$ min; ^1H NMR (400 MHz, D_2O , 25 °C) $\delta = 8.21$ (s, 1 H), 5.96 (d, $J = 6.0$ Hz, 1 H), 4.77 (dd, $J = 4.8, 6.0$ Hz, 1 H), 4.57 (dd, $J = 3.4, 4.8$ Hz, 1 H), 4.37 (dt, $J = 2.7, 3.0$ Hz, 1 H), 4.25–4.12 (m, 2 H), 1.11–0.14 (m, 3 H); ^{31}P NMR (162 MHz, D_2O , 25 °C) $\delta = 41.32$ (dt, $J = 40.04, 6.10$ Hz, 1 P) 34.37 (d, $J = 40.00$ Hz, 1 P); HRMS (ESI⁺) Calcd m/z for $\text{C}_{10}\text{H}_{17}\text{BN}_5\text{O}_{10}\text{P}_2^-$ (M-H⁺) 440.0549, found 440.0555 (**3b**) $R_t = 5.5$ min; ^1H NMR (400 MHz, D_2O , 25 °C) $\delta = 8.18$ (s, 1 H), 5.95 (d, $J = 6.0$ Hz, 1 H), 4.78 (dd, $J = 5.2, 6.0$ Hz, 1 H), 4.51 (dd, $J = 3.5, 5.2$ Hz, 1 H), 4.37 (td, $J = 3.0, 3.5$ Hz, 1 H), 4.28–4.13 (m, 2 H), 0.89–0.05 (m, 3 H) ^{31}P NMR (162 MHz, D_2O , 25 °C) $\delta =$; HRMS (ESI⁺) Calcd m/z for $\text{C}_{10}\text{H}_{17}\text{BN}_5\text{O}_{10}\text{P}_2^-$ (M-H⁺) 440.0549, found 440.0556. Exemplary previous synthesis: Li P. et al., *JACS*, **2005**, 127, 16782–16783.

5.3. Adenosine 5'-O-(1-thiodiphosphate); ADPaS (**4**).

4 (127 mg, 2670 opt.mu, 0.178 mmol, 61%; TEA salt) was obtained starting from 228 mg (4350 opt.mu, 0.290 mmol) of AMPS (TEA salt) following the general procedure 4.1. Coupling time: 3 d; deprotection time: 5 h. Diastereoisomers D1(**4a**) and D2 (**4b**) were later separated on semi-preparative RP HPLC and after repeated freeze-drying, were isolated as ammonium salts.

5.3.1. Microwave assisted synthesis of (**4**).

7 (143 mg, 3000 opt.mu, 0.200 mmol, 63%; TEA salt) was obtained starting from 250 mg of AMPS (TEA salt, 4770 opt.mu, 0.318 mmol) following the general procedure 4.2. Coupling time: 30 min; deprotection time: 20 min.

(**4a**) $R_t = 5.3$ min; ^1H NMR (400 MHz, D_2O , 25 °C) $\delta = 8.66$ (s, 1 H), 8.26 (s, 1 H), 6.16 (d, $J = 5.7$ Hz, 1 H), 4.82–4.81 (m, /overlapped by solvent/ 1 H), 4.59 (dd, $J = 4.1, 4.9$ Hz, 1 H), 4.45–4.40 (m, 1 H), 4.28–4.21 (m, 1 H); ^{31}P NMR (162 MHz, D_2O , 25 °C) $\delta = 43.40$ (d, $J = 27.0$ Hz, 1 P), -9.51 (d, $J = 27.0$ Hz, 1 P); HRMS (ESI⁺) Calcd m/z for $\text{C}_{10}\text{H}_{14}\text{N}_5\text{O}_9\text{P}_2\text{S}^-$ (M-H⁺) 441.9993, found 441.9980; (**4b**) $R_t = 6.3$ min; ^1H NMR (400 MHz, D_2O , 25 °C) $\delta = 8.61$ (s, 1 H), 8.27 (s, 1 H), 6.16 (d, $J = 6.0$ Hz, 1 H), 4.80 (dd, $J = 4.9, 6.0$ Hz, 1 H), 4.57 (dd, $J = 3.5, 4.9$ Hz, 1 H), 4.45–4.41 (m, 1 H), 4.30–4.25 (m, 2 H); ^{31}P NMR (162 MHz, D_2O , 25 °C) $\delta = 43.40$ (d, $J = 27.0$ Hz, 1 P), -9.51 (d, $J = 27.0$ Hz, 1 P); HRMS (ESI⁺) Calcd m/z for $\text{C}_{10}\text{H}_{14}\text{N}_5\text{O}_9\text{P}_2\text{S}^-$ (M-H⁺) 441.9993, found 441.9985; Exemplary previous synthesis: Li P. et al., *JACS*, **2005**, 127, 16782–16783.

5.4. Adenosine 5'-O-(1-boranodiphosphate); ADPaBH₃ (**5**).

5 (2340 opt.mu, 0.16 mmol, 65%, TEA salt) was obtained starting from crude AMPBH₃ (TEA salt, 3580 opt.mu, 0.24 mmol) following the general procedure 4.1. Coupling time: 24 h; deprotection time: 3 h.

5.4.1. Microwave assisted synthesis of (**5**).

5 (5460 opt.mu, 0.364 mmol, 58%; TEA salt) was obtained starting from crude AMPBH₃ (TEA salt, 9420 opt.mu, 0.63 mmol) following the general procedure 4.2. Coupling time: 30 min; deprotection time: 20 min.

(**5a**) $R_t = 6.0$ min; ^1H NMR (400 MHz, D_2O , 25 °C) $\delta = 8.57$ (s, 1 H), 8.22 (s, 1 H), 6.12 (d, $J = 5.7$ Hz, 1 H), 4.76 (dd, $J = 5.0, 5.7$ Hz, 1 H), 4.58 (dd, $J = 3.2, 5.0$ Hz, 1 H), 4.40 (td, $J = 3.0, 3.2$ Hz, 1 H), 4.30–4.13 (m, 2 H), 3.19 (q, $J = 7.5$ Hz, 12 H), 1.27 (t, $J = 7.5$ Hz, 18 H), 0.87–0.02 (m, 3 H); ^{31}P NMR (162 MHz, D_2O , 25 °C) $\delta = 82.50$ (m, 1 P), -10.68 (d, $J = 30.3$ Hz, 1 P); HRMS (ESI⁺) Calcd m/z for $\text{C}_{10}\text{H}_{19}\text{BN}_5\text{O}_{10}\text{P}_2^+$ (M+H⁺) 426.0746 found 426.0742. (**5b**) $R_t = 7.1$ min; ^1H NMR (400 MHz, D_2O , 25 °C) $\delta = 8.56$ (s, 1 H), 8.22 (s, 1 H), 6.12 (d, $J = 5.7$ Hz, 1 H), 4.76 (dd, $J = 5.0, 5.7$ Hz, 1 H), 4.52 (dd, $J = 3.4, 5.0$ Hz, 1 H), 4.40 (td, $J = 3.0, 3.4$ Hz, 2 H), 4.30–4.13 (m, 2 H), 0.87–0.02 (m, 3 H); ^{31}P NMR (162 MHz, D_2O , 25 °C) $\delta = 82.50$ (m, 1 P), -10.68 (d, $J = 30.3$ Hz, 1 P); HRMS (ESI⁺) Calcd m/z for $\text{C}_{10}\text{H}_{19}\text{BN}_5\text{O}_{10}\text{P}_2^+$ (M+H⁺) 426.0746, found 426.0744. Exemplary previous synthesis: Li P. et al. *JACS*, **2005**, 127, 16782–16783.

5.5. Uridine 5'-O-(1-thiodiphosphate); UDPaS (**6**).

6 (48 mg, 650 opt.mu, 0.067 mmol, 65%; TEA salt) was obtained starting from 53 mg (1000 opt.mu, 0.104 mmol) of UMPS (TEA salt) following the general procedure 4.1. Coupling time: 3 d; deprotection time: 5 h

(**6a**) $R_t = 4.7$ min; ^1H NMR (400 MHz, D_2O , 25 °C) $\delta = 8.09$ (d, $J = 8.2$ Hz, 1 H), 6.00 (d, $J = 4.3$ Hz, 1 H), 5.98 (d, $J = 8.2$ Hz, 1 H), 4.43–4.37 (m, 2 H), 4.35–4.24 (m, 3 H), 3.19 (q, $J = 7.5$ Hz, 12 H), 1.27 (t, $J = 7.5$ Hz, 18 H); ^{31}P NMR (162 MHz, D_2O , 25 °C) $\delta = 42.69$ (dt, $J = 28.6, 6.3$ Hz, 1 P) -11.34 (d, $J = 28.6$ Hz, 1 P); HRMS (ESI⁺) Calcd m/z for $\text{C}_9\text{H}_{13}\text{N}_2\text{O}_{11}\text{P}_2\text{S}^-$ (M-H⁺) 418.9721, found 418.9713; (**6b**) $R_t = 5.6$ min; ^1H NMR (400 MHz, D_2O , 25 °C) $\delta = 8.06$ (d, $J = 8.2$ Hz, 1 H), 6.00 (d, $J = 4.3$ Hz, 1 H), 5.98 (d, $J = 8.2$ Hz, 1 H), 4.43–4.37 (m, 2 H), 4.35–4.24 (m, 3 H), 3.19 (q, $J = 7.5$ Hz, 12 H), 1.27 (t, $J = 7.5$ Hz, 18 H); ^{31}P NMR (162 MHz, D_2O , 25 °C) $\delta = 42.53$ (dt, $J = 28.6, 6.3$ Hz, 1 P) -11.24 (d, $J = 28.6$ Hz, 1 P); HRMS (ESI⁺) Calcd m/z for $\text{C}_9\text{H}_{13}\text{N}_2\text{O}_{11}\text{P}_2\text{S}^-$ (M-H⁺) 418.9721, found 418.9713; Exemplary previous synthesis: Sheu K.R. et al., *Biochemistry*, **1979**, 18, 5548–5556.

5.6. N⁷-methylguanosine 5'-O-(1-thiodiphosphate) m⁷GDPaS (**7**).

7 (250 mg, 2560 opt.mu, 0.225 mmol, 39%; TEA salt) was obtained starting from 310 mg (6525 opt.mu, 0.572 mmol) of

m⁷GMPS (TEA salt) following the general procedure **4.1**. Coupling time: 3 d; deprotection time: 6 h. Diastereoisomers D1 (**7a**) and D2 (**7b**) were later separated on semi-preparative RP HPLC and after repeated freeze-drying, were isolated as ammonium salts.

5.6.1. Microwave assisted synthesis of (**7**).

7 (42 mg, 430 opt.mu, 0.038 mmol, 60%; TEA salt) was obtained starting from 34 mg of m⁷GMPS (TEA salt, 720 opt.mu, 0.063 mmol) following the general procedure **4.2**. Coupling time: 20 min; deprotection time: 20 min.

(**7a**) R_t = 5.0 min ¹H NMR (400 MHz, D₂O, 25 °C) δ = 9.30 (s, 1 H), 6.09 (d, *J* = 3.5 Hz, 1 H), 4.72 (dd, *J* = 3.5, 4.7 Hz, 1 H), 4.54 (dd, *J* = 4.7, 5.5 Hz, 1 H), 4.46–4.42 (m, 1 H), 4.37 (ddd, *J* = 2.2, 4.7, 12.0 Hz, 1 H), 4.28 (dd, *J* = 6.8, 12.0 Hz, 2 H), 4.16 (s, 3 H); ³¹P NMR (162 MHz, D₂O, 25 °C) δ = 43.73 (d, *J* = 28.0 Hz, 1 P), -10.66 (d, *J* = 28.0 Hz, 1 P); HRMS (ESI⁺) Calcd m/z for C₁₁H₁₆N₅O₁₀P₂S⁺ (M-H⁺) 472.0098, found 472.00826; (**7b**) R_t = 6.4 min ¹H NMR (400 MHz, D₂O, 25 °C) δ = 9.29 (s, 1 H), 6.08 (d, *J* = 3.2 Hz, 1 H), 4.71 (dd, *J* = 3.2, 5.0 Hz, 1 H), 4.53 (t, *J* = 5.0 Hz, 1 H), 4.46–4.42 (m, 1 H), 4.40 (dd, *J* = 5.3, 12.0 Hz, 1 H), 4.27 (dd, *J* = 6.0, 12.0 Hz, 1 H), 4.15 (s, 3 H); ³¹P NMR (162 MHz, D₂O, 25 °C) δ = 43.45 (d, *J* = 26.0 Hz, 1 P), -10.54 (d, *J* = 26.0 Hz, 1 P); HRMS (ESI⁺) Calcd m/z for C₁₁H₁₆N₅O₁₀P₂S⁺ (M-H⁺) 472.0098, found 472.0084.

5.7. Uridine 2',3'-O,O-cyclothiophosphate 5'-O-(1-thiodiphosphate); 2',3'-cyc-P_S-UDPaS (**8**).

8 (70 mg, 1015 opt.mu, 0.106 mmol, 59%; TEA salt) was obtained starting from 92 mg (1730 opt.mu 0.180 mmol) of 2',3'-cyc-P_S-UMPS (TEA salt) following the general procedure **4.1**. Coupling time: 5 d; deprotection time: 5 h. Diastereoisomers D1(**8a**) and D2 (**8b**) were later separated on semi-preparative RP HPLC and after repeated freeze-drying, were isolated as ammonium salts.

(**8a**) R_t = 2.6 min; ¹H NMR (400 MHz, D₂O, 25 °C) δ = 7.89 (d, *J* = 8.1 Hz, 1 H), 6.09 (d, *J* = 2.2 Hz, 1 H), 5.94 (d, *J* = 8.1 Hz, 1 H), 5.22 (dd, *J* = 2.2, 4.2 Hz, 1 H), 5.19 (dd, *J* = 1.6, 4.2 Hz, 1 H), 4.64–4.58 (m, 1 H), 4.29 (dd, *J* = 3.4, 6.3 Hz, 2 H); ³¹P NMR (162 MHz, D₂O, 25 °C), δ = 76.90 (t, *J* = 10.3 Hz, 1 P), 43.64 (dt, *J* = 27.8, 6.3 Hz, 1 P), -10.49 (d, *J* = 27.8 Hz, 1 P); HRMS (ESI⁺) Calcd m/z for C₉H₁₂N₂O₁₂P₃S₂⁺ (M-H⁺) 496.9050, found 496.9034; (**8b**) R_t = 2.8 min; ¹H NMR (400 MHz, D₂O, 25 °C) δ = 7.90 (d, *J* = 8.0 Hz, 1 H), 6.10 (br. s, 1 H), 5.95 (d, *J* = 8.0 Hz, 1 H), 5.24–5.21 (m, 1 H), 5.21–5.18 (m, 1 H), 4.65–4.58 (m, 1 H), 4.33–4.24 (m, 2 H); ³¹P NMR (162 MHz, D₂O, 25 °C) δ = 76.92 (t, *J* = 10.0 Hz, 1 P), 43.64 (dt, *J* = 27.8, 6.3 Hz, 1 P), -10.48 (d, *J* = 27.8 Hz, 1 P); HRMS (ESI⁺) Calcd m/z for C₉H₁₂N₂O₁₂P₃S₂⁺ (M-H⁺) 496.9050, found 496.9036.

5.8. Adenosine 5'-O-(1,2-dithiodiphosphate) ADPaSβS (**9**)

9 (48 mg, 840 opt.mu, 0.056 mmol, 20%, TEA salt) was obtained starting from 190 mg (4300 opt.mu, 0.287 mmol) of AMPS (TEA salt) following the general procedure **4.1**. Coupling time: 5 d; deprotection time: 5 h. D1 (**9a**) and D2 (**9b**) were later separated on semi-preparative RP HPLC and after repeated freeze-drying, were isolated as ammonium salts.

(**9a**) R_t = 4.5 min; ¹H NMR (400 MHz, D₂O, 25 °C) δ = 8.70 (s, 1 H), 8.24 (s, 1 H), 6.13 (d, *J* = 5.5 Hz, 1 H), 4.82 (dd, *J* = 5.0, 5.5 Hz, 1 H), 4.63 (dd, *J* = 4.0, 5.0 Hz, 1 H), 4.42–4.37 (m, 1 H), 4.36–4.28 (m, 1 H), 4.27–4.20 (m, 1 H); ³¹P NMR (162 MHz, D₂O, 25 °C) δ = 41.21 (d, *J* = 43.2 Hz, 1 P) 33.80 (d, *J* = 43.2 Hz, 1 P); Calcd m/z for C₁₀H₁₄N₅O₈P₂S₂⁺ (M-H⁺) 457.9764, found (**9a**) 457.9766; (**9b**) R_t = 5.2 min; ¹H NMR (400 MHz, D₂O, 25 °C) δ = 8.63 (s, 1 H), 8.24 (s, 1 H), 6.12 (d, *J* = 5.7 Hz, 1 H), 4.81 (dd, *J* = 5.0, 5.7 Hz, 1 H), 4.64 (dd, *J* = 3.5, 5.0 Hz, 1 H), 4.42–4.38 (m, 1 H), 4.36–4.29 (m, 1 H), 4.28–4.20 (m, 1 H); ³¹P NMR (162 MHz, D₂O, 25 °C) δ = 40.66 (dt, *J* = 41.0, 6.5 Hz, 1P) 33.75 (d, *J* = 41.0 Hz, 1 P); HRMS (ESI⁺) Calcd m/z for C₁₀H₁₄N₅O₈P₂S₂⁺ (M-H⁺) 457.9764, found 457.9768; Exemplary previous synthesis: Ahmadibeni J. et al., *Org.Lett.*, **2005**, 7 (25), 5589–5592.

5.9. Guanosine 5'-O-(1,2-dithiodiphosphate) GDPαSβS (**10**).

10 (85 mg, 1460 opt.mu, 0.121 mmol, 36%, TEA salt) was obtained starting from 182 mg (4000 opt.mu, 0.332 mmol) of GMPS (TEA salt) following the general procedure **4.1**. Coupling time: 5 d; deprotection time: 5 h.

5.9.1. Microwave assisted synthesis of (**10**).

10 (25 mg, 430 opt.mu, 0.036 mmol, 30%; TEA salt) was obtained starting from 55 mg of GMPS (TEA salt, 1445 opt.mu, 0.120 mmol) following the general procedure **4.2**. Coupling time: 15 min; deprotection time: 30 min.

(**10a**) R_t = 2.0 min; ¹H NMR (400 MHz, D₂O, 25 °C) δ = 8.25 (s, 1 H) 5.91 (d, *J* = 6.10 Hz, 1 H) 4.82 (dd, *J* = 6.10, 5.20 Hz, 1 H) 4.62 (dd, *J* = 5.20, 3.00 Hz, 1 H) 4.34–4.38 (m, 1 H) 4.23–4.32 (m, 2 H); Calcd m/z for C₁₀H₁₄N₅O₉P₂S₂⁺ (M-H⁺) 473.9714, found 473.9716; (**10b**) R_t = 3.6 min; ¹H NMR (400 MHz, D₂O, 25 °C) δ = 8.25 (s, 1 H), 5.90 (d, *J* = 6.0 Hz, 1 H), 4.80 (dd, *J* = 5.0, 6.0 Hz, 1 H), 4.61 (dd, *J* = 3.5, 5.0 Hz, 1 H), 4.37–4.33 (m, 1 H), 4.30–4.23 (m, 2 H) ³¹P NMR (162 MHz, D₂O, 25 °C) δ = 41.26 (dt, *J* = 40.00, 6.10 Hz, 1 P) 33.81 (d, *J* = 40.00 Hz, 1 P); HRMS (ESI⁺) Calcd m/z for C₁₀H₁₄N₅O₉P₂S₂⁺ (M-H⁺) 473.9714, found 473.9701. Exemplary previous synthesis: Ludwig J. et al., *JOC*, **1991**, 56, 5860–5865.

5.10. Adenosine 5'-O-(2-thiotriphosphate) ATPβS (**11**).

11 (39 mg, 1012 opt.mu, 0.067 mmol, 62%; TEA salt) was obtained starting from 70 mg (1630 opt.mu, 0.109 mmol) of

ADP β S (TEA salt) following the general procedure 4.1. Coupling time: 2 h; deprotection time: 12 h.

$R_t = 3.9$ min; ^1H NMR (400 MHz, D_2O , 25 $^\circ\text{C}$) $\delta = 8.61$ (s, 1 H), 8.32 (s, 1 H), 6.17 (d, $J = 6.2$ Hz, 1 H), 4.86 (dd, $J = 4.5$, 6.2 Hz, 1 H), 4.68–4.64 (m, 1 H), 4.46–4.41 (m, 1 H), 4.44–4.29 (m, 1 H), 4.29–4.22 (m, 1 H); (11a) ^{31}P NMR (162 MHz, D_2O , 25 $^\circ\text{C}$) $\delta = 30.72$ (m, 1 P), -10.69 (d, $J = 22.0$ Hz, 1 P), -11.31 (d, $J = 25.9$ Hz, 1 P) (11b) ^{31}P NMR, (162 MHz, D_2O , 25 $^\circ\text{C}$): $\delta = 30.72$ (m, 1 P), -10.69 (d, $J = 22.0$ Hz, 1 P), -11.31 (d, $J = 25.9$ Hz, 1 P); HRMS (ESI $^-$) Calcd m/z for $\text{C}_{10}\text{H}_{15}\text{N}_5\text{O}_{12}\text{P}_3\text{S}^-$ (M-H $^+$) 521.9656; found 521.9640. Exemplary previous synthesis: Goody R. S. & Eckstein F., *Biochemistry*, **1976**, 15, 1685–91.

5.11. Guanosine 5'-O-(2-thiotriphosphate); GTP β S (12).

12 (59 mg, 1290 opt.mu, 0.107 mmol, 73%) was obtained starting from 67 mg (1750 opt.mu, 0.145 mmol) of GDP β S (TEA salt) following the general procedure 4.1. Coupling time: 24 h; deprotection time: 5 h.

$R_t = 2.1$ min; ^1H NMR (400 MHz, D_2O , 25 $^\circ\text{C}$) $\delta = 8.18$; 8.17* (s, 1 H), 5.95 (d, $J = 6.5$ Hz, 1 H), 4.87 (m, 1 H), 4.64 (m, 1 H), 4.38 (m, 1 H), 4.31 (m, 1 H), 4.24 (m, 1 H); (12a) ^{31}P NMR (162 MHz, D_2O , 25 $^\circ\text{C}$) $\delta = 30.51$ (t, $J = 26.9$ Hz, 1 P), -10.72 (d, $J = 26.9$ Hz, 1 P), -11.34 (d, $J = 26.9$ Hz, 1 P); (12b) ^{31}P NMR (162 MHz, D_2O , 25 $^\circ\text{C}$) $\delta = 30.54$ (t, $J = 26.9$ Hz, 1 P), -10.72 (d, $J = 26.9$ Hz, 1 P), -11.34 (d, $J = 26.9$ Hz, 1 P); HRMS (ESI $^-$) Calcd m/z for $\text{C}_{10}\text{H}_{15}\text{N}_5\text{O}_{13}\text{P}_3\text{S}^-$ (M-H $^+$) 537.9605; found 537.9590. Exemplary previous synthesis: Connolly B. et al, *Biochemistry*, **1982**, 21, 1983–1989.

5.12. Adenosine 5'-O-(2-boranotriphosphate); ATP β BH $_3$ (13).

13 (65.5 mg, 1600 opt.mu, 0.107 mmol, 47%; TEA salt) was obtained starting from 100 mg of AMP-Im/ Na^+ (3400 opt.mu, 0.240 mmol) and boranophosphate (TEA salt, 280 mg, 1.44 mmol) following the general procedure 4.1. Coupling time: 5 h; deprotection time: 2 h. 13 was later converted into ammonium salt on semi-preparative RP HPLC and repeatedly freeze-dried.

5.12.1. Microwave assisted synthesis of (13).

13 (33 mg, 800 opt.mu, 0.054 mmol, 20%; TEA salt) was obtained starting from 150 mg of AMP-Im/ Na^+ (4000 opt.mu, 0.267 mmol) and boranophosphate (TEA salt, 314 mg, 1.60 mmol) following the general procedure 4.2. Coupling time: 5 min; deprotection time: 5 min.

$R_t = 3.6$ min; ^1H NMR (400 MHz, D_2O , 25 $^\circ\text{C}$) $\delta = 8.44$ (s, 1 H), 8.13 (s, 1 H), 6.03 (d, $J = 6.0$ Hz, 1 H), 4.69 (dd, $J = 5.0$, 6.0 Hz, 1 H), 4.51 (dd, $J = 3.0$, 5.0 Hz, 1 H), 4.35–4.31 (m, 1 H), 4.17 (s, 2 H), 4.19–4.14 (m, 2 H), 0.81–0.03 (m, 3 H); ^{31}P NMR (162 MHz, D_2O , 25 $^\circ\text{C}$) $\delta = 72.39$ –76.45 (m, 1 P) -10.81 (d, $J = 30.8$ Hz, 1 P) -11.29 (d, $J = 32.5$ Hz, 1 P);

HRMS (ESI $^-$) Calcd m/z for $\text{C}_{10}\text{H}_{18}\text{BN}_5\text{O}_{12}\text{P}_3^-$ (M-H $^+$) 504.0263; found 504.02494.

5.13. Guanosine 5'-O-(2-boranotriphosphate); GTP β BH $_3$ (14).

14 (37.1 mg, 1002 opt.mu, 0.083 mmol, 18%; TEA salt) was obtained starting from GMP-Im/ Na^+ 235 mg (5640 opt.mu, 0.470 mmol) and boranophosphate (TEA salt, 553 mg, 2.82 mmol) following the general procedure 4.1. Coupling time: 5 h; deprotection time: 2 h. 14 was later converted into ammonium salt on semi-preparative RP HPLC and repeatedly freeze-dried.

$R_t = 2.6$ min; ^1H NMR (400 MHz, D_2O , 25 $^\circ\text{C}$) $\delta = 8.17$ (s, 1 H) 5.97 (d, $J = 6.5$ Hz, 1 H) 4.85 (dd, $J = 6.5$, 5.0 Hz, 1 H) 4.62 (s, 1 H) 4.60–4.64 (m, 1 H) 4.38–4.43 (m, 1 H) 4.24–4.30 (m, 2 H); ^{31}P NMR (162 MHz, D_2O , 25 $^\circ\text{C}$) $\delta = 74.60$ (s, 1 P) 65.23–76.25 (m, 1 P) -10.47 (d, $J = 26.4$ Hz, 1 P) -11.26 (d, $J = 32.5$ Hz, 1 P); HRMS (ESI $^-$) Calcd m/z for $\text{C}_{10}\text{H}_{18}\text{BN}_5\text{O}_{13}\text{P}_3^-$ (M-H $^+$) 520.0212; found 520.0196.

5.14. Adenosine 5'-O-(2-selenotriphosphate) ATP β Se (15) (microwave assisted synthesis)

15 (21.2 mg, 560 opt.mu, 0.037 mmol, 43%) was obtained starting from 42.6 mg (1305 opt.mu, 0.086 mmol) of ADP β Se (TEA salt) following the general procedure 4.2. Coupling time: 30 min; deprotection time: 5 min. 15 was later converted into ammonium salt on semi-preparative RP HPLC and repeatedly freeze-dried.

$R_t = 3.8$ min; ^1H NMR (400 MHz, D_2O , 25 $^\circ\text{C}$) $\delta = 8.54$ (s, 1 H), 8.22 (s, 1 H), 6.11 (d, $J = 5.8$ Hz, 1 H), 4.81 (dd, $J = 5.0$, 5.8 Hz, 1 H), 4.64 (s, 1 H), 4.67–4.62 (m, 1 H), 4.38 (s, 1 H), 4.41–4.36 (m, 1 H), 4.33–4.15 (m, 2 H) (15a) ^{31}P NMR (162 MHz, D_2O , 25 $^\circ\text{C}$) $\delta = 16.35$ (dd, $J = 31.7$, 30.8 Hz, 1 P) -11.99 (d, $J = 30.8$ Hz, 1 P) -12.57 (d, $J = 31.7$ Hz, 1 P) (15b) ^{31}P NMR (162 MHz, D_2O , 25 $^\circ\text{C}$) $\delta = 16.30$ (dd, $J = 31.7$, 30.8 Hz, 1 P) -11.99 (d, $J = 30.8$ Hz, 1 P) -12.57 (d, $J = 31.7$ Hz, 1 P) HRMS (ESI $^-$) Calcd m/z for $\text{C}_{10}\text{H}_{15}\text{N}_5\text{O}_{12}\text{P}_3\text{Se}^-$ (M-H $^+$) 569.9101 found 569.9088.

5.15. Guanosine 5'-O-(2-selenotriphosphate) GTP β Se (16).

16 (11.1 mg, 230 opt.mu, 0.019 mmol, 15%; TEA salt) was obtained starting from 85.2 mg (1530 opt.mu, 0.127 mmol) of GDP β Se (TEA salt) following the general procedure 4.1. Coupling time: 24 h; deprotection time: 2 h. 16 was later converted into ammonium salt on semi-preparative RP HPLC and repeatedly freeze-dried.

$R_t = 2.6$ min. ^1H NMR (400 MHz, D_2O , 25 $^\circ\text{C}$) $\delta = 8.13$ (s, 1 H), 5.90 (d, $J = 6.1$ Hz, 1 H), 4.81 (dd, $J = 5.1$, 6.1 Hz, 1 H), 4.62–4.58 (m, 1 H), 4.36–4.31 (m, 1 H), 4.30–4.17 (m, 2 H) ^{31}P NMR (162 MHz, D_2O , 25 $^\circ\text{C}$) $\delta = 16.56$ (s, 1 P) -11.97 (d, $J = 30.5$ Hz, 1 P) -12.67 (d, $J = 30.5$ Hz, 1 P) HRMS (ESI $^-$)

) Calcd m/z for $C_{10}H_{15}N_5O_{13}P_3Se^-$ ($M-H^+$) 585.9050 found 585.90584.

5.16. Adenosine 5'-O-(1,2-methylenetriphosphate); ppCH₂pA (17).

17 (68 mg, 1263 opt.mu, 84 mmol, 77%; TEA salt) was obtained starting from 68 mg (1640 opt.mu, 0.109 mmol) of ppCH₂pA (TEA salt) following the general procedure **4.1**. Coupling time: 1.5 h; Deprotection time: 4 h. **17** was later converted into ammonium salt on semi-preparative RP HPLC and repeatedly freeze-dried.

$R_t = 4.0$ min; 1H NMR (400 MHz, D₂O, 25 °C) $\delta = 8.56$ (s, 1 H), 8.26 (s, 1 H) 6.14 (d, $J = 5.7$ Hz, 1 H), 4.85–4.80 (m, 1 H), 4.58 (t, $J = 4.7$, 4.2 Hz 1 H), 4.46–4.42 (m, 1 H), 4.40–4.36 (m, 1 H), 4.27 (dd, $J = 4.0$, 8.2 Hz, 1 H), 2.38 (t, $J = 20.4$ Hz, 2 H) ^{31}P NMR (162 MHz, D₂O, 25 °C) $\delta = 18.67$ (td, $J = 21.5$, 9.3 Hz, 1 P) 7.29 (dtd, $J = 24.9$, 21.5, 21.5, 9.5 Hz, 1 P) -8.80 (d, $J = 24.9$ Hz, 1 P); HRMS (ESI⁺) Calcd m/z for $C_{11}H_{16}N_5O_{12}P_3^-$ ($M-H^+$) 504.0092, found 504.0077. Exemplary previous synthesis: Spelta V., et al. *Br. J. Pharmacol.* **2003**, 140(6), 1027–34.

5.17. Guanosine 5'-O-(1,2-methylenetriphosphate); ppCH₂pG (18).

18 (64 mg, 930 opt.mu, 0.078 mmol, 78%; TEA salt) was obtained starting from 65 mg (1200 opt.mu, 0.100 mmol) of pCH₂pG (TEA salt) following the general procedure **4.1**. Coupling time: 1.5 h; Deprotection time: 4 h. **18** was later converted into ammonium salt on semi-preparative RP HPLC and repeatedly freeze-dried.

5.17.1. Microwave assisted synthesis of (18).

18 (32 mg, 470 opt.mu, 0.039 mmol, 80%; TEA salt) was obtained starting from 30 mg of pCH₂pG (TEA salt) (590 opt.mu, 0.049 mmol) following the general procedure **4.2**. Coupling time: 30 min; Deprotection time: 20 min.

$R_t = 2.6$ min; 1H NMR (400 MHz, D₂O, 25 °C) $\delta = 8.15$ (s, 1 H) 5.93 (d, $J = 6.2$ Hz, 1 H) 4.83 (dd, $J = 6.2$, 5.0 Hz, 1 H) 4.57 (dd, $J = 5.0$, 3.4 Hz, 1 H) 4.32–4.37 (m, 1 H) 4.16–4.21 (m, 2 H) 2.37 (t, $J = 20.4$ Hz, 2 H); ^{31}P NMR (162 MHz, D₂O, 25 °C) $\delta = 18.37$ (td, $J = 20.4$, 8.5 Hz, 1 P) 7.53 (dtd, $J = 24.7$, 20.4, 20.4, 8.5 Hz, 1P) -9.90 (d, $J = 24.9$ Hz, 1 P); HRMS (ESI⁺) Calcd m/z for $C_{11}H_{17}N_5O_{13}P_3^-$ ($M-H^+$) 520.0041, found 520.0024. Exemplary previous synthesis: Rydzik A.M. et al., *J. Org. Biomol. Chem.* **2009**, 7, 4763–76.

5.18. Adenosine 5'-O-(1,2-imidotriphosphate) ppNHpA (19).

20 (52 mg, 969 opt.mu, 0.064 mmol, 76%; TEA salt) was obtained starting from 53 mg (1260 opt.mu, 0.084 mmol) of pNHpA (TEA salt) following the general procedure **4.1**. Coupling time: 2 h; Deprotection time: 4 h. **19** was later converted into ammonium salt on semi-preparative RP HPLC and repeatedly freeze-dried.

$R_t = 3.4$ min; 1H NMR (400 MHz, D₂O, 25 °C) $\delta = 8.57$ (s, 1 H), 8.26 (s, 1 H), 6.15 (d, $J = 5.7$ Hz, 1 H), 4.82 (dd, $J = 5.7$, 5.0 Hz, 1 H), 4.61 (dd, $J = 5.0$, 3.5 Hz, 1 H), 4.39–4.43 (m, 1 H), 4.18–4.25 (m, 1 H), 4.12–4.18 ppm (m, 1 H); ^{31}P NMR (162 MHz, D₂O) $\delta = 0.68$ (dt, $J = 6.3$, 5.7 Hz, 1 P) -9.51 (d, $J = 21.0$ Hz, 1 P) -11.16 (dd, $J = 21.0$, 6.3 Hz, 1 P); HRMS (ESI⁺) Calcd m/z for $C_{11}H_{17}N_5O_{12}P_3^-$ ($M-H^+$) 505.0092, found 505.0027. Exemplary previous synthesis: Ma Q. et al., *JACS*, **1988**, 110, 4060–4061.

5.19. Guanosine 5'-O-(1,2-imidotriphosphate) ppNHpG (20).

20 (108 mg, 1600 opt.mu, 0.134 mmol, 72%; TEA salt) was obtained starting from 158 mg (2230 opt.mu, 0.185 mmol) of pNHpG (TEA salt) following the general procedure **4.1**. Coupling time: 1.5 h; Deprotection time: 4 h. **20** was later converted into ammonium salt on semi-preparative RP HPLC and repeatedly freeze-dried.

$R_t = 4.0$ min; 1H NMR (400 MHz, D₂O, 25 °C) $\delta = 8.29$ (s, 1 H), 5.95 (d, $J = 6.0$ Hz, 1 H), 4.81 (dd, $J = 5.0$, 6.0 Hz, 1 H), 4.57 (dd, $J = 3.7$, 5.0 Hz, 1 H), 4.39–4.34 (m, 1 H), 4.21–4.14 (m, 2 H); ^{31}P NMR (162 MHz, D₂O, 25 °C) $\delta = 0.62$ (dt, $J = 6.0$, 5.9 Hz, 1 P) -9.74 (d, $J = 20.5$ Hz, 1 P) -11.10 (dd, $J = 20.5$, 6.1 Hz, 1 P); HRMS (ESI⁺) Calcd m/z for $C_{11}H_{17}N_5O_{13}P_3^-$ ($M-H^+$) 520.9994, found 520.9988.

5.20. Adenosine 5'-O-tetraphosphate ppppA (21).

21 (90 mg, 1500 opt.mu, 0.1 mmol, 82% TEA salt) was obtained starting from ATP (97 mg, 1830 opt.mu, 0.12 mmol, TEA salt) following the general procedure **4.1**. Coupling time: 3 h; Deprotection time: 3 h. **21** was later converted into ammonium salt on semi-preparative RP HPLC and repeatedly freeze-dried.

$R_t = 3.0$ min; 1H NMR (400 MHz, D₂O, 25 °C) $\delta = 8.44$ (s, 1 H), 8.12 (s, 1 H), 6.06 (d, $J = 6.1$ Hz, 1 H), 4.72 (dd, $J = 5.0$, 6.1 Hz, 1 H), 4.55 (dd, $J = 3.0$, 5.0 Hz, 1 H), 4.40–4.35 (m, 1 H), 4.30–4.15 (m, 2 H); ^{31}P NMR (162 MHz, D₂O, 25 °C) $\delta = -10.12$ (d, $J = 18.6$ Hz, 1 P) -11.07 (d, $J = 18.6$ Hz, 1 P) -22.68 (m, 2 P); HRMS (ESI⁺) Calcd m/z for $C_{10}H_{18}N_5O_{16}P_4$ ($M+H^+$) 587.9699, found 587.9690.

5.21. N⁷-methylguanosine 5'-O-(2,3-methylenetetraphosphate); ppCH₂pp(m⁷G) (22).

23 (45 mg, 500 opt.mu, 0.044 mmol, 56%; TEA salt) was obtained from pCH₂pp(m⁷G) 85 mg (890 opt.mu, 0.078 mmol, TEA salt) following the general procedure **4.1**. Coupling time: 3.5 h; deprotection time: 2 h; **22** was later converted into ammonium salt on semi-preparative RP HPLC and repeatedly freeze-dried.

$R_t = 3.5$ min. 1H NMR (400 MHz, D₂O, 25 °C) $\delta = 6.08$ (d, $J = 3.7$ Hz, 1 H), 4.74 (dd, $J = 5.0$, 3.7 Hz, 1 H), 4.60 (dd, $J = 5.0$, 4.0 Hz, 1 H), 4.38–4.43 (m, 1 H), 4.28–4.36 (m, 1 H),

4.18–4.25 (m, 1 H), 4.15 (s, 3 H), 2.46 (t, $J = 20.0$ Hz, 2 H); ^{31}P NMR (162 MHz, D_2O , 25 °C) $\delta = 17.66$ (td, $J = 20.0$, 9.0 Hz, 1 P), 8.50 (dtd, $J = 21.0$, 20.0, 9.0 Hz, 1 P), -10.51 (d, $J = 21.0$ Hz, 1 P), -22.74 (t, $J = 21.0$ Hz, 1 P); HRMS (ESI $^-$) Calcd m/z for $\text{C}_{12}\text{H}_{20}\text{N}_5\text{O}_{16}\text{P}_4^-$ (M-H^+) 613.9861; found 613.9871.

5.22. N^7 -methylguanosine 5'- O -(1,2-methylenetetraphosphate); pppCH₂p($m^7\text{G}$) (23).

23 (52 mg, 580 opt.mu, 0.051 mmol, 51%; TEA salt) was obtained starting from ppCH₂p($m^7\text{G}$) (102 mg, 1140 opt.mu, 0.10 mmol, TEA salt) following the general procedure **4.1**. Coupling time: 4h; Deprotection time: 2 h. **23** was later converted into ammonium salt on semi-preparative RP HPLC and repeatedly freeze-dried.

$R_t = 3.5$ min; ^1H NMR (400 MHz, D_2O , 25 °C) $\delta = 6.03$ (d, $J = 3.7$ Hz, 1 H), 4.67 (dd, $J = 3.7$, 5.0 Hz, 1 H), 4.51 (dd, $J = 4.0$, 5.0 Hz, 1 H), 4.39–4.35 (m, 1 H), 4.33–4.27 (m, 1 H), 4.25–4.19 (m, 1 H), 4.09 (s, 3 H), 2.45 (t, $J = 20.8$ Hz, 2 H); ^{31}P NMR (162 MHz, D_2O , 25 °C) $\delta = 8.28$ (dtd, $J = 25.5$, 20.8, 9.0 Hz, 1 P), 6.35 (dtd, $J = 25.5$, 20.8, 9.0 Hz, 1 P), -9.85 (d, $J = 25.5$ Hz, 1 P), -11.12 (d, $J = 25.5$ Hz, 1 P); HRMS (ESI $^-$) Calcd m/z for $\text{C}_{12}\text{H}_{20}\text{N}_5\text{O}_{16}\text{P}_4^-$ (M-H^+) 613.9861; found 518.9869.

5.23. Guanosine 5'- O -(1,2-methylene-3-thiotriphosphate); pspCH₂pG (24) (microwave assisted synthesis)

24 (28 mg, 530 opt.mu, 0.047 mmol, 70%; TEA salt) was obtained starting from 44 mg (800 opt.mu, 0.067 mmol) of pCH₂pG (TEA salt) following the general procedure **4.2**. Coupling time: 30 min; deprotection time: 30 min. **24** was later converted into ammonium salt on semi-preparative RP HPLC and repeatedly freeze-dried.

$R_t = 3.9$ min; ^1H NMR (400 MHz, D_2O , 25 °C) δ 8.29 (s, 1 H), 5.97 (d, $J = 5.9$ Hz, 1 H), 4.84 (dd, $J = 4.5$, 5.9 Hz, 1 H), 4.61 (dd, $J = 3.5$, 4.5 Hz, 1 H), 4.40–4.35 (m, 1 H), 4.26–4.21 (m, 2 H), 2.52 (t, $J = 20.1$ Hz, 2 H); ^{31}P NMR (162 MHz, D_2O , 25 °C) $\delta = 33.23$ (d, $J = 32.0$ Hz, 1 P), 19.86 (tdt, $J = 20.1$, 7.6, 5.0, Hz, 1 P), 7.02 (dtd, $J = 32.0$, 20.1, 7.6 Hz, 1 P); HRMS (ESI $^-$) Calcd m/z for $\text{C}_{11}\text{H}_{18}\text{N}_5\text{O}_{16}\text{P}_4^-$ (M-H^+) 535.9704; found 535.9820.

6. Supplementary references.

Burgers, P. M. J.; Eckstein, F. *Biochemistry* **1979**, *18*, 592-596.

Jones J.W., Robins R.K., *JACS.*, **1963**, *85*, 193–201.

Kalek M., Jemielity J., Stepinski J., Stolarski R., Darzynkiewicz E., *Tetrahedron Lett.*, **2005**, *46*, 2417-2421

Kowalska J., Lewdorowicz M., Darzynkiewicz E. and Jemielity J., *Tet. Lett.*, **2007**, *48*, 5475

Kowalska J., Lukaszewicz M., Zuberek J., Darzynkiewicz. E., Jemielity J., *ChemBioChem*, **2009**, *15*, 2469

Mukaiyama T. and Hashimoto M., *Bull. Chem. Soc. Jpn.*, **1971**, *44*, 2284-2284


Nahum V., Fischer B., *Eur. J. Inorg. Chem.*, **2004**, 4124


Rydzik A. M., Lukaszewicz M., Zuberek J., Kowalska J., Darzynkiewicz Z. M., Darzynkiewicz E. and Jemielity J., *Org. Biomol. Chem.*, **2009**, *7*, 4763


Yoshikawa M., Sakuraba M. and Kusashio K., *Bull. Chem. Soc. Jpn.*, **1970**, *43*, 456

Tomasz J., Vaghefi M.M., Ratsep P.C., Willis R.C. and Robins R.K., *Nucl. Acids Res.* **1988**, *16*, 8645

IV.HPLC profiles, HRMS and NMR spectra










Im-p₅-EtCN/Li⁺ (1b) MS (-)ES (Calc. [M-H]⁻ C₆H₇N₃O₂P₅⁻ 216.0002



(1b) Im-p₅-EtCN/Li⁺








(2a) GDP α S/ NH_4^+ D1





GDP α S/ NH_4^+ D1 (2a) HPLC

GDPαS/NH₄⁺ D1 (2a) HRMS (-)ES (Calc. [M-H]⁻ C₁₀H₁₄N₅O₁₀P₂S⁻ 457.9942


20306gdpas1 #1-61 RT: 0.01-2.17 AV: 61 NL: 1.08E3
T: FTMS - c ESI Full ms [100.00-1000.00]










(2b) GDP α S/NH $_4^+$ D2




GDP α S/NH $_4^+$ D2 (2b) HPLC











(3a) GDP α BH₃/NH₄⁺ D1





GDP α BH₃/NH₄⁺ D1 (3a) HPLC


MS

GDPcBH₃/NH₄⁺ D1 (3a) MS (-)ES (Calc. [M-H]⁻ C₁₀H₁₇BN₃O₁₀P₂⁻ 440.0549



120705gdpabh3d1 #6-140 RT: 0.09-2.19 AV: 135 NL: 1.37E5
T: FTMS - p ESI Full ms [150.00-1000.00]










(3b) GDP α BH₃/NH₄⁺ D2





GDP α BH₃/NH₄⁺ D2 (3b) HPLC








(4a) ADP α S/NH $_4^+$ D1





ADP α S/NH $_4^+$ D1 (4a) HPLC

ADPαS/NH₄⁺ D1 (4a) HRMS (ESI) (Calc. [M-H]⁺ C₁₀H₁₄N₅O₉P₂S⁺ 441.9993



20306adpas1 #1-31 RT: 0.00-1.08 AV: 31 NL: 3.19E3
T: FTMS - c ESI Full ms [100.00-1000.00]








(4b) ADP α S/ NH_4^+ D2





ADP α S/ NH_4^+ D2 (4b) HPLC

ADPaS/NH₄⁺ D2 (4b) HRMS (-)ES (Calc. [M+H]⁺ C₁₀H₁₄N₅O₉P₂S⁻ 441.9993



20306adpas2 #2-33 RT: 0.04-1.15 AV: 32 NL: 7.45E3
T: FTMS - c ESI Full ms [100.00-1000.00]









(5) ADP α BH₃/TEA⁺ D1D2mix




ADP α BH₃/TEA⁺ D1D2mix (5) HPLC



ADP α BH₃/TEA⁺ D1D2mix (5) MS (-)ES (Calc. [M-H]⁻ C₁₀H₁₇BN₅O₃P₂ 424.0600








(6) UDP α S/TEA⁺ D1D2mix




UDP α S/TEA⁺ D1D2mix (6) HPLC


UDPaS/TEA D1(6) MS (-)ES (Calc. [M+H]⁺ C₉H₁₃N₂O₁₁P₂S⁺ 418.9721


20403udpas1_120403135853 #1-46 RT: 0.00-0.80 AV: 46 NL: 1.13E4
T: FTMS - p ESI Full ms [100.00-1000.00]





UDPaS/TEA (6) MS (-)ES (Calc. [M-H] C₉H₁₃N₂O₁₁P₂S
418.9721










(7a) m⁷GDPαS/NH₄⁺ D1





m⁷GDPαS/NH₄⁺ D1 (7a) HPLC










(7b) m⁷GDPαS/NH₄⁺ D2





m⁷GDPαS/NH₄⁺ D2 (7b) HPLC








(8a) 2',3'-cyc-P₅-UDPαS/NH₄⁺ D1




2',3'-cyc-P₅-UDPαS/NH₄⁺ D1 (8a) HPLC

2',3'-cyc-P₅-UDPαS/NH₄⁺ D1 (8a) MS (-)ES (Calc. [M-H]⁻ C₉H₁₂N₂O₁₂P₅S₂⁻ 496.9050



20306psudpas1 #1-26 RT: 0.01-0.91 AV: 26 NL: 7.42E3
T: FTMS - c ESI Full ms [100.00-1000.00]








(8b) 2',3'-cyc-P₅-UDPαS/NH₄⁺ D2





2',3'-cyc-P₅-UDPαS/NH₄⁺ D2 (8b) HPLC

2',3'-cyc-P₅-UDPaS/NH₄⁺ D2 (8b) HRMS (-)ES (Calc. [M-H]⁻ C₉H₁₂N₂O₁₂P₃S₂⁻ 496.905



20306psudpas2 #3-86 RT: 0.08-3.07 AV: 84 NL: 1.18E4
T: FTMS - c ESI Full ms [100.00-1000.00]








(9a) ADP α S β S/NH $_4^+$ D1





ADP α S β S/TNH $_4^+$ D1 (9a) HPLC

ADPaSβS/NH₄⁺ D1 (9a) HRMS (-)ES (Calc. [M-H]⁻ C₁₀H₁₄N₃O₈P₂S₂⁻ 457.9764



120309apsp1 #2-33 RT: 0.04-1.10 AV: 32 NL: 4.09E4
T: FTMS - p ESI Full ms [100.00-1200.00]









(9b) ADP α S β S/NH $_4^+$ D2




ADP α S β S/TNH $_4^+$ D2 (9b) HPLC



ADPαSβS/NH₄⁺ D2 (9b) HRMS (-)ES (Calc. [M-H]⁻ C₁₀H₁₄N₅O₈P₂S₂⁻ 457.9764








(10a) GDP α S β S/ NH_4^+ D1





GDP α S β S/ NH_4^+ D1 (10a) HPLC

GDPαSβS/NH₄⁺ D1 (10a) HRMS (-)ES (Calc. [M-H]⁻ C₁₀H₁₄N₅O₉P₂S₂⁻ 473.9714



120309gpsps1 #15-33 RT: 0.42-1.04 AV: 19 NL: 4.34E4
T: FTMS - p ESI Full ms [100.00-1000.00]








(10b) GDP α SBS/NH $_4^+$ D2





GDP α SBS/NH $_4^+$ D2 (10b) HPLC

GDP α S β S/NH $_4^+$ D21 (10b) HRMS (-)ES (Calc. [M-H] $^-$ C $_{10}$ H $_{14}$ N $_5$ O $_9$ P $_2$ S $_2$) 473.9714



20306gpsps2 #7-153 RT: 0.23-5.48 AV: 147 NL: 4.09E3
T: FTMS - c ESI Full ms [100.00-1000.00]










(11) ATP β S/TEA⁺ D1D2mix





ATP β S S/TEA⁺ D1D2mix (11) HPLC








(12) GTP β S/TEA⁺ D1D2mix





GTP β S/TEA⁺ D1D2mix (12) HPLC

GTP β S /TEA⁺ D1D2mix (12) MS (-)ES (Calc. [M-H]⁻ C₁₀H₁₅N₃O₁₃P₃S⁻ 537.9605



20306gppsp #1-26 RT: 0.01-0.91 AV: 26 NL: 2.64E3
T: FTMS - c ESI Full ms [100.00-1000.00]








(13) ATPβBH₃/TEA⁺ D1D2mix





ATPβBH₃/TEA⁺ D1D2mix (13) HPLC

ATPβBH₃/TEA⁺ D1D2mix (13) MS (-)ES (Calc. [M-H]⁻ C₁₀H₁₈BN₅O₁₂P₃⁻ 504.0263



20306appbp #2-40 RT: 0.05-1.41 AV: 39 NL: 2.75E3
T: FTMS - c ESI Full ms [100.00-1000.00]








(14) GTP β BH₃/TEA⁺ D1D2mix





GTP β BH₃/TEA⁺ D1D2mix (14) HPLC

GTP β BH $_3$ /TEA $^+$ D1D2mix (14) MS (-)ES (Calc. [M-H] $^-$ C $_{10}$ H $_{18}$ BN $_5$ O $_3$ P $_3$) 520.0212



20306gppbp #3-36 RT: 0.08-1.27 AV: 34 NL: 4.78E2
T: FTMS - c ESI Full ms [100.00-1000.00]









(15) ATP β Se/TEA⁺ D1D2mix




ATP β Se/TEA⁺ D1D2mix (15) HPLC



ATPβSe/TEA+ D1D2mix (15) MS (-)ES (Calc. [M-H]⁻ C₁₀H₁₅N₅O₁₂P₃Se⁻ 569.9101








(16) GTP β Se/ NH_4^+ D1D2mix




GTP β Se/ NH_4^+ D1D2mix (16) HPLC


MS

120705GppSEP #6-87 RT: 0.08-1.36 AV: 82 NL: 1.29E5
T: FTMS - p ESI Full ms [150.00-1000.00]





GTPβSe/NH₄⁺ D1D2mix (16) MS (-)ES (Calc. [M-H]⁻ C₁₀H₁₅N₅O₁₃P₃Se⁻ 585.9050






(17) ppCH₂pA/NH₄⁺





ppCH₂pA/NH₄⁺ (17) HPLC

ppCH₂pA / NH₄⁺ (17) HRMS (-)ES (Calc. [M-H]⁻ C₁₁H₁₆N₅O₁₂P₃⁻ 504.0092



20306apch2pp #1-31 RT: 0.01-1.09 AV: 31 NL: 1.63E4
T: FTMS - c ESI Full ms [100.00-1000.00]








(18) ppCH₂pG /NH₄⁺





ppCH₂pG /NH₄⁺ (18) HPLC

ppCH₂pG /NH₄⁺ (18) HRMS (-)ES (Calc. [M-H]⁻ C₁₁H₁₇N₃O₃P₃⁻ 520.0041



20306gpch2pp #1-41 RT: 0.01-1.45 AV: 41 NL: 4.36E3
T: FTMS - c ESI Full ms [100.00-1000.00]








(19) ppNHpA /NH₄⁺





ppNHpA /NH₄⁺ (19) HPLC

ppNHpA /NH₄⁺ (19) HRMS (-) ES (Calc. [M-H]⁻ C₁₁H₁₇N₅O₁₂P₃⁻ 505.0092



20306apnhpp #2-24 RT: 0.05-0.84 AV: 23 NL: 1.34E3
T: FTMS - c ESI Full ms [100.00-1000.00]










(20) ppNHpG /NH₄⁺





ppNHpG /NH₄⁺ (20) HPLC








(21) ppppA / NH₄⁺





ppppA) / NH₄⁺ (21) HPLC

ppppA / NH₄⁺ (21) MS (-)ES (Calc. [M-H]⁻ C₁₀H₁₆N₅O₁₈P₄: 585.9548



120718ap4 #1-20 RT: 0.01-0.31 AV: 20 NL: 1.09E6
T: FTMS + p ESI Full ms [150.00-1000.00]








(22) ppCH₂pp(m⁷G) / NH₄⁺





ppCH₂pp(m⁷G) / NH₄⁺ (22) HPLC

ppCH₂pp(m⁷G) / NH₄⁺ (22) MS (-)ES (Calc. [M-H]⁻ C₁₂H₂₀N₅O₁₆P₄⁻ 613.9861



120705m7gpch2ppp #17-83 RT: 0.26-1.24 AV: 67 NL: 8.84E4
T: FTMS - p ESI Full ms [150.00-1000.00]










(23) pppCH₂p(m⁷G) / NH₄⁺





pppCH₂p(m⁷G) / NH₄⁺ (23) HPLC







(24) $p_s p_{CH_2} pG / NH_4^+$



$p_s p_{CH_2} pG / NH_4^+$ (24) HPLC

p₅p_{CH₂}pG / NH₄⁺ (24) MS (-)ES (Calc. [M-H]⁻ C₁₁H₁₇N₅O₁₂P₃S⁻ 535.9813

